VIB305 / Vibrant Sciences Limited - LARVOL DELTA

A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=146 | Recruiting | Sponsor: Vibrant Sciences Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Vibrant Therapeutics Raises $61M and Appoints Han Lee, Ph.D. as Co-CEO (Businesswire) - "...U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its lead program, VIB305, for the treatment of EGFR-positive solid tumors....Proceeds from the financing will be used to advance Vibrant’s robust pipeline, as well as further develop its proprietary next-generation drug design platform and expand the company’s team to support continued growth and global development activities."

Financing • IND • Solid Tumor